Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

吉利德科学（Gilead Sciences）与默沙东（MSD，美国和加拿大称为 Merck & Co）宣布，其开发的一款抗逆转录病毒组合疗法可能成为每周一次的口服 HIV 药物。在一项 II 期临床试验中，该组合疗法通过每周一次口服剂量即可抑制 HIV 病毒，为患者带来了新治疗选择的希望。

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...